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Abstract
Background: Due to increasing co-morbidity associated with aging, heart failure (HF) has 
become more prevalent and heterogeneous in older individuals, and non-cardiovascular (CV) 
mortality has increased. Previously, we defined a multi-marker modality that included cystatin C  
(CysC), troponin T (TnT), and age. Here, we validated this multi-marker risk score by evalu-
ating its predictions of all-cause mortality and CV mortality in an independent population of 
older individuals with HF and reduced ejection fraction (HFrEF).
Methods: This prospective cohort study included 124 patients, median age 73 years, that had 
HFrEF. We determined all-cause mortality and CV mortality at a 3-year follow-up. We com-
pared the risk score to the N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) 
for predicting all-cause mortality and CV mortality.
Results: High risk scores were associated with both all-cause mortality (HR 4.2, 95% CI 
2.2–8.1, p < 0.001) and CV mortality (HR 3.6, 95% CI 1.7–8.0, p = 0.0015). Receiver ope-
rating characteristics showed similar efficacy for the risk score and NT-proBNP in predicting 
all-cause mortality (HR 0.74, 95% CI 0.65–0.81 vs. HR 0.74, 95% CI 0.65–0.81, p = 0.99) 
and CV mortality (HR 0.68, 95% CI 0.59–0.76 vs. HR 0.67, 95% CI 0.58–0.75, p = 0.95). 
When the risk score was added to the NT-proBNP, the continuous net reclassification impro-
vement was 56% for predicting all-cause mortality (95% CI 18–95%, p = 0.004) and 45% for 
predicting CV mortality (95% CI 2–89%, p = 0.040).
Conclusions: In HFrEF, a risk score that included age, TnT, and CysC showed efficacy 
similar to the NT-proBNP for predicting all-cause mortality and CV mortality in an older 
population. (Cardiol J 2015; 22, 1: 31–36)
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Introduction
Approximately 1–2% of the population in the 
western world has heart failure (HF) [1]. The 
prevalence of HF exceeds 8% among individuals 
over 75 years old [1]. The annual mortality varies 
from 5% [2] to 75% in cases of end-stage HF [3]. 
This broad range indicates that the prognosis is 
extremely diverse and can be difficult to assess 
in individual patients. In older patients with HF 
that have a reduced ejection fraction (HFrEF), 
about two thirds of deaths have been attributed to 
cardiovascular (CV) causes [4]. Therefore, appro-
ximately one third of deaths are due to non-CV 
causes. These latter causes are probably related 
to the increasing rate of co-morbidity; thus, HF 
appears to be heterogeneous in older individuals.
We previously developed a prognostic model 
that aimed to account for individual variations and 
confounding factors due to comorbidity in older 
individuals. This model comprised 3 risk markers 
that were highly associated with all-cause mor-
tality [5]. The model produced a risk score that 
reflected the severity of the 3 risk markers: age, 
serum troponin T (TnT), and serum cystatin C 
(CysC) [5]. Each risk marker defined as age > 75 
years, TnT > 10 ng/L and CysC > 1.3 mg/L adds 
1 point respectively in the risk score with total 
score levels ranging from 0 (lowest risk) to 3 points 
(highest risk).
The present study aimed to evaluate this risk 
score in a validation cohort of older patients with 
HFrEF.
Methods
Study cohort and diagnosis
This prospective study included patients 
scheduled to undergo echocardiography at the 
Department of Clinical Physiology, Sahlgrenska 
University Hospital, Gothenburg, Sweden, in 2010. 
Eligible patients had a final diagnosis of HFrEF 
based on HF symptoms and a left ventricular 
ejection fraction (LVEF) < 50% [6]. Two patients 
were excluded from the study due to the lack of 
a Swedish identification number, which would make 
any follow-up impossible.
All patients underwent echocardiography, 
blood sampling, and a clinical examination within 
approximately 24 h after echocardiography. Echo-
cardiograms were analyzed by an echocardiography 
specialist, independent of the study investigators, 
who was blinded to other variables in this study.
The study protocol was approved by the 
Ethics Committee at the University of Gothenburg. 
Written informed consent was obtained from all 
the patients and the study protocol conformed to 
the ethical guidelines of the 1975 Declaration of 
Helsinki.
Laboratory analyses
The N-terminal prohormone of B-type natriu-
retic peptide (NT-proBNP), CysC, high-sensitivity-
-TnT and creatinine measurements were obtained 
from the routine laboratory services provided by 
the Clinical Chemistry Laboratory at Sahlgrenska 
University Hospital. The estimated glomerular 
filtration rate was calculated according to the 
Cockcroft-Gault formula. The performance of the 
laboratory assays was described previously [7, 8].
Follow-up and outcomes
All patients were followed up at 3 years. Data 
on the causes of death were obtained from the death 
registry of the National Board of Health and Welfare 
in Sweden. Outcome measures were all-cause mor-
tality and CV mortality. The causes of death were 
classified according to the International Statistical 
Classification of Diseases and Related Health Prob-
lems, 10th revision (ICD-10). The automatic coding 
of medical entities (ACME) system [9] was used to 
select the underlying cause of death. ACME used 
the ICD codes and their locations recorded on the 
death certificate for determining the cause of death. 
CV mortality was defined as an underlying cause of 
death that was classified as I05-I09 (chronic rheuma-
tic heart diseases), I20-I51 (ischemic heart disease, 
pulmonary heart disease, diseases of pulmonary 
circulation, and other forms of heart disease), or 
I60-I69 (cerebrovascular diseases).
Statistical analyses
Kaplan-Meier analyses were used to evaluate 
possible associations between mortality and the 
risk scores. Hazard ratios (HR) with confidence 
intervals were calculated to evaluate risks. Uni-
variate comparisons between dead and alive at 
3 years were calculated with median tests. Di-
chotomous variables were analyzed with Monte-
-Carlo estimates. Receiver operating characteristic 
(ROC) curves were used to assess the prognostic 
properties of the risk score and the NT-proBNP 
classification. Areas under the ROC curves (AUC) 
were compared with the DeLong methodology [10]. 
Statistical analyses were performed with SPSS 
version 20 and Medcalc 12. All probabilities were 
2-tailed, and p values < 0.05 were considered signi-
ficant. NT-proBNP levels were classified based on 
3 previously defined risk groups [5] (low risk 
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< 2000 ng/L, medium risk = 2000–8000 ng/L, 
and high risk ≥ 8000 ng/L). Reclassification im-
provement was assessed with the continuous net 
reclassification improvement (NRI) method [11], 
because appropriate risk levels depend on the cli-
nical situation and available resources. One patient 
(survivor at 3 years) was excluded from statistical 
analyses of laboratory data and the risk score due 
to the lack of available laboratory results.
Results
Baseline characteristics
The study participants comprised a represen-
tative population of individuals with HFrEF. They 
had a median age of 73 years (interquartile range 
64–80 years). Baseline characteristics for patients 
that had died or survived at the 3-year follow up 
are presented in Table 1.
All-cause and cardiovascular mortality
In this cohort, all-cause mortality was 30% and 
CV mortality was 21%. The risk score was able 
to separate individuals with low risk (0–1 score 
points) from those with moderate-high risk (2–3 
score points) for all-cause mortality (HR 4.2, 95% 
confidence interval [CI] 2.2–8.1, p < 0.001, 0–1 
vs. 2–3 score points; Fig. 1) and for CV mortality 
(HR 3.6, 95% CI 1.7–8.0, p = 0.0015, 0–1 vs. 2–3 
score points; Fig. 2). The probabilities of survival 
for patients in the 3 different classes of NT-proBNP 
are presented in Figures 3 and 4 for comparison.
Table 1. Baseline characteristics of patients that survived or died at the 3-year follow-up.
Variable Survived (n = 87) Died (n = 37) P
Clinical data
Age 72 (63–78) 78 (71–84) 0.20
Gender — male 72% 73% 1.0
Systolic BP [mm Hg] (median + IQR) 125 (110–150) 125 (110–145) 0.88
Diastolic BP [mm Hg] (median + IQR) 75 (65–87) 70 (70–80) 0.70
Echocardiogram parameters
LVEF [%] 35 (30–40) 33 (25–40) 0.86
LVDD [cm] (median + IQR) 6 (5–6) 6 (5–7) 0.98
PA [mm Hg] (median + IQR) 38 (30–45) 42 (30–50) 0.36
Stroke volume (median + IQR) 53 (44–65) 52 (41–59) 1.0
Cardiovascular risk factors
Smoking 30% 35% 0.67
Hypertension 38% 35% 0.84
Diabetes mellitus 20% 35% 0.071
Cardiovascular disease
Myocardial infarction 45% 43% 1.0
Angina pectoris 5.7% 8.1% 0.70
Atrial fibrillation 38% 35% 0.84
Comorbidity
Pulmonary disease 21% 24% 0.81
Stroke 9.2% 22% 0.079
Renal failure (GFR < 60) 35% 73% < 0.001
Medications
ACE inhibitors 52% 32% 0.052
Beta-blockers 83% 70% 0.15
Diuretics 51% 84% 0.001
Laboratory markers
S-creatinine [µmol/L] (median + IQR) 92 (74–106) 121 (89–176) 0.016
Estimated GFR [mL/min] (median + IQR) 75 (56–98) 43 (29–62) 0.001
Cystatin C [mg/L] (median + IQR) 1.0 (0.82–1.2) 1.7 (1.2–2.2) < 0.001
High-sensitivity-troponin T [ng/L] (median + IQR) 24 (8–63) 49 (24–105) 0.016
NT-proBNP [ng/L] (median + IQR) 1670 (569–3410) 5890 (2200–20600) 0.016
ACE — angiotensin converting enzyme inhibitor; BP — blood pressure; GFR — glomerular filtration rate; IQR — interquartile range;  
LVDD — left ventricular end-diastolic diameter; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal pro B-type natriuretic peptide; 
PA — pulmonary artery
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There was no difference in the AUCs between 
the predictions assessed with the risk score and 
those assessed with the NT-proBNP for either 
all-cause mortality (HR 0.74, 95% CI 0.65–0.81 
vs. HR 0.74, 95% CI 0.65–0.81, p = 0.99) or CV 
mortality (HR 0.68, 95% CI 0.59–0.76 vs. HR 0.67, 
95% CI 0.58–0.75, p = 0.95). However, when the 
risk score was added to the NT-proBNP classifica-
tion, the NRI for predicting all-cause mortality was 
56% (95% CI 18–95%, p = 0.004) and the NRI for 
predicting CV mortality was 45% (95% CI 2–89%, 
p = 0.040).
Subgroup analyses of patients with  
NT-proBNP < 2500 ng/L and ≥ 2500 ng/L
The risk score was able to differentiate risk 
levels in a subgroup of patients with NT-proBNP 
< 2500 ng/L. Two groups were distinguished for 
all-cause mortality (p < 0.046; scores 0–1 vs. 2–3 
points) and for CV mortality (p = 0.040; scores 
0–1 vs. 2–3 points). In a subgroup of patients with 
NT-proBNP ≥ 2500 ng/L, the risk score also dif-
ferentiated two risk groups for all-cause mortality 
(p < 0.021; scores 0–1 vs. 2–3 points), but not for 
CV mortality (p = 0.13; scores 0–1 vs. 2–3 points).
Figure 1. Association between the risk score and all-
-cause mortality. The risk score ranged from 0 to 
3 points. The lines indicate the survival probability for 
individuals with the indicated scores, over the 3-year 
study period; p < 0.001 for comparison between indivi-
duals with 0–1 vs. 2–3 points.
Figure 2. Association between the risk score and car-
diovascular mortality. The risk score ranged from 0 to 
3 points. The lines indicate the survival probability for 
individuals with the indicated scores, over the 3-year 
study period; p = 0.0015 for comparison between indi-
viduals with 0–1 vs. 2–3 points.
Discussion
This study examined a real-life cohort of older 
patients with HF to assess our previously deve-
loped multi-marker prognostic risk score, which 
included age, TnT, and CysC [5]. Our present 
results showed that the efficacy of our risk score 
was similar to that of the NT-proBNP classification 
for predicting all-cause mortality and CV mortality. 
Moreover, a combination of both the risk score 
and the NT-proBNP classification provided higher 
prognostic value than the NT-proBNP classification 
alone, for both all-cause and CV mortality.
In our cohort, approximately 70% of patients 
died from CV causes. This was consistent with 
results from previous studies. Henkel et al. [4] 
found that CV mortality constituted 64% of all 
deaths in a cohort aged 75.0 ± 12.7 years with 
HFrEF. Another study by Mehta et al. [11] showed 
that CV mortality constituted 86% of all deaths in 
a cohort aged 75.2 ± 12.4 years.
The present validation cohort was diffe-
rent from our previous HF cohort in 3 important 
aspects: (1) This study was conducted prospecti-
vely in patients scheduled to undergo echocardio-
34 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 1
graphy due to clinically suspected HF. Therefore, 
there was a short time delay between echocardio-
graphy and biomarker analyses; (2) Patients with 
LVEF ≥ 50% were excluded in this validation co-
hort; (3) The present validation cohort consisted 
of patients referred to echocardiography both from 
the hospital and from primary care; in contrast, the 
score was previously developed with patients in 
hospital care. Despite these differences in cohorts, 
the risk score remained effective for predicting 
adverse outcomes.
Compared to the NT-proBNP classification, 
the score had several main advantages. (1) It 
provided complementary prognostic information 
to the NT-proBNP for predicting both all-cause 
and CV-mortality, as indicated by the NRI; (2) The 
risk score could stratify risk among patients with 
relatively low levels of NT-proBNP (< 2500 ng/L). 
Among this group of patients, the all-cause mortali-
ty was 35% different between patients with scores 
of 0–1 points vs. those with scores of 2–3 points 
(data not shown). Precise prognostic information 
is important for tailoring treatment to individual 
patients and/or for facilitating the allocation of li-
mited health care resources; (3) It could be argued 
that the risk score may be less influenced than NT-
-proBNP levels by analytical and intra-individual 
variations [12, 13], which might compromise the 
accuracy of prognostic assessments; (4) The risk 
score takes into account renal function and high-
-sensitivity TnT levels, both known markers of 
risk in HF. In fact, CysC has been shown to be 
a stronger predictor of mortality than creatinine in 
older patients with HF [14]. Moreover, de Antonio 
et al. [15] found that high-sensitivity TnT provided 
prognostic information in patients with HF with 
a median age of 70.3 years, even after adjustment 
for NT-proBNP and other risk factors.
Our proposed risk score is simpler to apply 
than, for instance, the Seattle Heart Failure Model 
[16] and the MAGGIC risk score [17]. This facility 
might encourage broader implementation, because 
busy clinicians must typically prioritize multiple 
tasks. Therefore, we anticipate that our suggested 
risk score may be a valuable tool in clinical practice 
in the future. However, one potential weakness in 
this study was a rather small sample size.
Conclusions
In HFrEF, a risk score that included age, TnT, 
and CysC had an accuracy similar to that of the NT-
-proBNP classification for predicting both all-cause 
mortality and CV mortality. A combination of the NT-
-proBNP and the risk score provided high prognostic 
value for predicting both all-cause and CV mortality.
Figure 4. Association between different N-terminal pro 
B-type natriuretic peptide (NT-proBNP) risk levels (low 
risk < 2000 ng/L, medium risk = 2000–8000 ng/L, and 
high risk ≥ 8000 ng/L) and cardiovascular mortality 
(p < 0.001).
Figure 3. Association between different N-terminal 
pro B-type natriuretic peptide (NT-proBNP) risk levels 
(low risk < 2000 ng/L, medium risk = 2000–8000 ng/L, 
and high risk ≥ 8000 ng/L) and all-cause mortality 
(p < 0.001).
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